- Home
- SCYX vs KUKE Comparison
SCYX vs KUKE Comparison
Compare SCYX & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- KUKE
- Stock Information
- Founded
- SCYX 1999
- KUKE 2002
- Country
- SCYX United States
- KUKE China
- Employees
- SCYX N/A
- KUKE N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- KUKE Other Consumer Services
- Sector
- SCYX Health Care
- KUKE Real Estate
- Exchange
- SCYX Nasdaq
- KUKE Nasdaq
- Market Cap
- SCYX 36.8M
- KUKE 30.4M
- IPO Year
- SCYX 2014
- KUKE 2021
- Fundamental
- Price
- SCYX $0.88
- KUKE $3.17
- Analyst Decision
- SCYX
- KUKE
- Analyst Count
- SCYX 0
- KUKE 0
- Target Price
- SCYX N/A
- KUKE N/A
- AVG Volume (30 Days)
- SCYX 204.8K
- KUKE 8.9K
- Earning Date
- SCYX 05-15-2025
- KUKE 06-10-2025
- Dividend Yield
- SCYX N/A
- KUKE N/A
- EPS Growth
- SCYX N/A
- KUKE N/A
- EPS
- SCYX N/A
- KUKE N/A
- Revenue
- SCYX $2,630,000.00
- KUKE $9,442,397.00
- Revenue This Year
- SCYX $460.12
- KUKE N/A
- Revenue Next Year
- SCYX $253.87
- KUKE N/A
- P/E Ratio
- SCYX N/A
- KUKE N/A
- Revenue Growth
- SCYX N/A
- KUKE N/A
- 52 Week Low
- SCYX $0.72
- KUKE $1.45
- 52 Week High
- SCYX $2.60
- KUKE $33.60
- Technical
- Relative Strength Index (RSI)
- SCYX 48.64
- KUKE 33.83
- Support Level
- SCYX $0.72
- KUKE $3.21
- Resistance Level
- SCYX $1.02
- KUKE $3.43
- Average True Range (ATR)
- SCYX 0.08
- KUKE 0.23
- MACD
- SCYX 0.00
- KUKE -0.15
- Stochastic Oscillator
- SCYX 51.70
- KUKE 0.00
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.